New York State Teachers Retirement System Has $3.25 Million Holdings in Catalyst Pharmaceuticals, Inc. $CPRX

New York State Teachers Retirement System lifted its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 0.4% in the second quarter, HoldingsChannel.com reports. The fund owned 149,887 shares of the biopharmaceutical company’s stock after buying an additional 577 shares during the period. New York State Teachers Retirement System’s holdings in Catalyst Pharmaceuticals were worth $3,253,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in CPRX. GAMMA Investing LLC boosted its position in shares of Catalyst Pharmaceuticals by 26.2% during the 1st quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company’s stock worth $68,000 after acquiring an additional 579 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in shares of Catalyst Pharmaceuticals by 65.0% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 35,334 shares of the biopharmaceutical company’s stock worth $857,000 after acquiring an additional 13,915 shares in the last quarter. Envestnet Portfolio Solutions Inc. acquired a new stake in shares of Catalyst Pharmaceuticals during the 1st quarter worth approximately $211,000. Cambridge Investment Research Advisors Inc. acquired a new stake in shares of Catalyst Pharmaceuticals during the 1st quarter worth approximately $484,000. Finally, Retirement Guys Formula LLC acquired a new stake in shares of Catalyst Pharmaceuticals during the 1st quarter worth approximately $231,000. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ:CPRX opened at $21.01 on Tuesday. The company has a market cap of $2.57 billion, a price-to-earnings ratio of 12.73, a PEG ratio of 0.82 and a beta of 0.79. The firm has a 50 day simple moving average of $20.27 and a 200 day simple moving average of $21.89. Catalyst Pharmaceuticals, Inc. has a one year low of $19.05 and a one year high of $26.58.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its quarterly earnings data on Monday, September 25th. The biopharmaceutical company reported $0.28 EPS for the quarter. The business had revenue of $53.11 million during the quarter. Catalyst Pharmaceuticals had a net margin of 37.36% and a return on equity of 40.78%. As a group, analysts expect that Catalyst Pharmaceuticals, Inc. will post 1.9 EPS for the current year.

Catalyst Pharmaceuticals declared that its Board of Directors has initiated a stock buyback plan on Wednesday, October 1st that allows the company to repurchase $200.00 million in shares. This repurchase authorization allows the biopharmaceutical company to purchase up to 8.3% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s board believes its stock is undervalued.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 30,000 shares of the company’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $20.30, for a total value of $609,000.00. Following the completion of the transaction, the insider directly owned 271,039 shares in the company, valued at approximately $5,502,091.70. This represents a 9.97% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Steve Miller sold 115,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 26th. The shares were sold at an average price of $20.28, for a total transaction of $2,332,200.00. Following the completion of the transaction, the insider owned 949,663 shares of the company’s stock, valued at approximately $19,259,165.64. This trade represents a 10.80% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 243,970 shares of company stock valued at $4,927,241. Insiders own 10.40% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on CPRX. Weiss Ratings reiterated a “hold (c+)” rating on shares of Catalyst Pharmaceuticals in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Sunday, October 12th. Finally, Zacks Research lowered shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 19th. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, Catalyst Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $33.20.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.